What are CNVs and how are they detected?

28 May 2025
Introduction to CNVs

Copy number variations (CNVs) are a form of structural variation in the genome that involve changes in the number of copies of a particular gene or genomic region. Unlike single nucleotide polymorphisms (SNPs) that involve a change in a single base pair, CNVs can encompass larger segments of DNA, ranging from a kilobase to several megabases. These variations can have significant implications, as they may lead to differences in gene expression, contribute to genetic diversity, and influence susceptibility to various diseases.

The Role of CNVs in Human Health

CNVs are known to play a vital role in human health and disease. Some CNVs are benign, contributing to the natural genetic variability among individuals. However, others can be deleterious, leading to developmental disorders or increasing the risk of conditions such as cancer, neurological disorders, and autoimmune diseases. For example, duplications or deletions in specific genomic regions have been linked to autism spectrum disorders, schizophrenia, and certain congenital anomalies.

Detecting CNVs: Techniques and Challenges

Identifying CNVs in the genome requires sophisticated techniques due to their size and complexity. Several methods have been developed to detect CNVs, each with its own strengths and weaknesses.

1. Array-Based Comparative Genomic Hybridization (aCGH)

One of the most established methods for detecting CNVs is array-based comparative genomic hybridization (aCGH). This technique involves comparing the DNA of a test sample to a reference sample to identify differences in DNA copy number. While aCGH can detect large CNVs across the genome, it may miss smaller variations or those in repetitive regions.

2. Next-Generation Sequencing (NGS)

Next-generation sequencing (NGS) has revolutionized CNV detection by providing high-resolution data that allows for the identification of a wide range of CNVs, from small to large. NGS can analyze the entire genome or target specific regions, offering precise information about CNV breakpoints and their genomic context. However, data interpretation can be complex, requiring advanced bioinformatics tools and expertise.

3. Polymerase Chain Reaction (PCR)-Based Methods

Real-time PCR and digital PCR are also used to detect CNVs, particularly when targeting known CNVs associated with specific diseases. These methods are highly sensitive and can quantify the copy number of a specific gene or region. While useful for confirmatory testing, they are not suitable for genome-wide CNV analysis.

4. Single Nucleotide Polymorphism (SNP) Arrays

SNP arrays provide another approach to CNV detection by analyzing variations in SNP patterns across different genomic regions. This method can be effective for identifying CNVs in large cohorts, but it may not capture all CNVs, particularly those in regions with low SNP density.

The Future of CNV Research and Clinical Applications

As technology advances, the ability to detect and analyze CNVs will continue to improve, potentially uncovering new insights into their role in human health and disease. In clinical settings, CNV analysis is becoming an integral part of genetic testing, helping to diagnose genetic disorders, guide treatment decisions, and inform genetic counseling.

Moreover, ongoing research into CNVs holds promise for personalized medicine, where understanding an individual’s genomic landscape could lead to tailored therapies and interventions. The integration of CNV data with other genomic and clinical information will enhance our understanding of complex diseases and contribute to the development of more effective treatment strategies.

Conclusion

Copy number variations are a crucial aspect of genetic diversity and play a significant role in health and disease. Detecting CNVs accurately requires a combination of advanced techniques and bioinformatics tools. As research progresses, our understanding of CNVs will continue to expand, offering new opportunities for improving human health through personalized approaches to medicine.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.